Webinar: GPEx® Lightning: Achieving Rapid, High-Titer Expression for Next-Generation Biologics

For nearly three decades, Catalent Biologics has built capabilities and expertise in development, manufacturing, and analytical services, now spanning new biological entities, biosimilars, plasmid DNA, cell and gene therapies, vaccines, sterile injectables, mRNA, and antibody-drug conjugates. It has developed processes for hundreds of biologic products, with more than 50 commercially approved products that have employed Catalent Biologics’ manufacturing and packaging capabilities as well as 20 approved/authorized biotherapeutics that have leveraged GPEx® cell line development technology. Using advanced technologies and tailored solutions from clinical to commercial supply, Catalent brings better biologic and advanced treatments to patients, faster.